Bensky MJ, Ayalon-Dangur I, Ayalon-Dangur R et al (2019) comparison of sublingual vs
a growth hormone-releasing factor analog, is FDA-approved for the treatment of HIV-associated lipodystrophy , with studies showing significant reduction in visceral adipose tissue (VAT) after 26 weeks of useSource: Falutz et al., New England Journal of Medicine, 2010
To learn more about our Peptide Therapy Program and how it can support your health and performance, schedule a consultation with us at SMaRT Health & Wellness
This evaluation reviews current health status, lab work, medications, and the patients specific goals to determine which combination makes clinical sense
Peer-reviewed research Not for human consumption